

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-6. (Canceled).

7. (Currently Amended) A method of inhibiting migration of human microvascular endothelial cells (HMVECs) expressing a native Robo-4 receptor, the method comprising exposing said HMVECs to a Slit Slit2 ligand or a HMVEC migration inhibiting fragment thereof, wherein exposing said HMVECs to said Slit Slit2 ligand inhibits migration of said HMVECs.

8. (Canceled).

9. (Previously Presented) The method of claim [[8]] Z, wherein exposing said HMVECs to a Slit2 ligand comprises exposing said HMVECs to a human Slit2 ligand or a HMVEC migration inhibiting fragment thereof.

10-22. (Canceled).